STOCK TITAN

Cybin Inc. - CYBN STOCK NEWS

Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.

Cybin Inc. (symbol: CYBN) is a pioneering biopharmaceutical company dedicated to addressing mental health challenges through innovative therapeutics. Specializing in psychedelic-based therapies, Cybin focuses on developing novel compounds, delivery mechanisms, and protocols aimed at treating a range of psychiatric and neurological conditions.

Cybin's core business revolves around advancing clinical-stage programs designed to harness the potential of psychedelics. The company is engaged in creating safe and effective treatments for conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD). Their research and development efforts highlight the transformative potential of these therapies in modern medicine.

Recently, Cybin has achieved significant milestones, including progress in their proprietary drug delivery technologies. These advancements aim to improve the administration and efficacy of psychedelic compounds, ensuring patients receive the maximum therapeutic benefit. Their innovative approach extends to developing new chemical entities (NCEs) that hold promise in the field of mental health treatment.

Financially, Cybin remains robust and committed to its growth strategy. The company has secured strategic partnerships and collaborations that bolster its research initiatives and clinical trials. These alliances are crucial in accelerating the development and commercialization of their therapeutic solutions.

Cybin's product pipeline is impressive, featuring multiple candidates in various stages of development. These include CYB001, a formulation targeting major depressive disorder, and CYB003, designed for anxiety disorders. Each product undergoes rigorous testing to ensure safety and effectiveness.

In summary, Cybin Inc. is at the forefront of revolutionizing mental health treatment through psychedelic-based therapies. Their dedication to advancing science and addressing unmet medical needs positions them as a significant player in the biopharmaceutical industry.

Rhea-AI Summary

Cybin Inc. has announced that its subsidiary, Adelia Therapeutics, achieved significant milestones as outlined in a December 2020 agreement. This includes a payment of $2,033,309.79 to Adelia shareholders, tied to milestone achievements. Class B shares will be issued, exchangeable for Cybin common shares at a rate of 10 to 1. The process for exchange is scheduled over the next two years. Cybin continues its mission to develop safe therapeutics to address mental health issues, leveraging innovative drug discovery and delivery systems.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
none
-
Rhea-AI Summary

Cybin has launched the EMBARK Psychedelic Facilitator Training Program, led by a team of 28 experts, aiming to enhance the training of psychedelic-assisted psychotherapy facilitators. This comprehensive program emphasizes ethical education and prepares facilitators to handle diverse participant experiences through six clinical domains and four care cornerstones. The initiative reflects Cybin's commitment to advancing therapeutic practices in the psychedelic field and supporting mental health treatment. The company continues to focus on psychedelic health innovations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.95%
Tags
none
-
Rhea-AI Summary

Cybin Inc. has published a peer-reviewed article detailing EMBARK, a model of psychedelic-assisted psychotherapy aimed at improving treatment effectiveness for mental health issues. Published on June 2, 2022, in Frontiers in Psychology, the article outlines EMBARK's six clinical domains: Existential-Spiritual, Mindfulness, Body Aware, Affective-Cognitive, Relational, and Keeping Momentum. The model responds to existing gaps in psychedelic therapy, integrating evidence-based practices and ethical considerations. Upcoming clinical trials will utilize EMBARK to support study participants using proprietary psychedelic molecules CYB003 and CYB004.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.95%
Tags
none
Rhea-AI Summary

Cybin Inc. will host a Key Opinion Leader webinar on June 9, 2022, from 11:00 a.m. ET to 12:00 p.m. ET. Featured speakers include renowned experts Dr. John Krystal from Yale School of Medicine and Dr. David Nutt from Imperial College London, who will discuss the evolving psychedelics landscape and emerging therapeutic options. The event, moderated by Doug Drysdale, Cybin's CEO, aims to shed light on the potential of psychedelic-based treatments for mental health disorders. Registration is available on Cybin's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.52%
Tags
conferences
-
Rhea-AI Summary

Cybin has submitted an Investigational New Drug (IND) application to the FDA for its CYB003, a deuterated psilocybin analog, aiming to treat major depressive disorder (MDD). This milestone follows successful IND-enabling work, with expectations to initiate Phase 1/2a clinical trials in mid-2022. The trial is a randomized, double-blind, placebo-controlled study that will assess the rapid onset of antidepressant effects and safety. Preliminary pharmacokinetic and safety data are expected by year-end 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.1%
Tags
-
Rhea-AI Summary

Cybin Inc. will participate in the morning trading bell ceremony at the New York Stock Exchange on May 18, 2022. As the first psychedelics company listed on the NYSE since August 5, 2021, Cybin is committed to transforming mental health treatments through innovative psychedelic therapies. Following the ceremony, in-person meetings with institutional investors will occur on May 18 and 19 in New York City. For inquiries, contact Cybin Investor Relations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.12%
Tags
conferences
Rhea-AI Summary

Cybin Inc. (NYSE American: CYBN) has announced that CEO Doug Drysdale will participate in a fireside chat during the H.C. Wainwright Global Investment Hybrid Conference from May 23-26, 2022, at Fontainebleau Miami Beach. The live webcast of the chat is scheduled for May 25, 2022, at 12:30 p.m. ET. Interested listeners can access the event through the company's investor relations website.

Cybin focuses on developing psychedelics into therapeutics, working with a network of partners to create effective treatments for mental health challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.46%
Tags
conferences
-
Rhea-AI Summary

Cybin Inc. and Kernel announce positive pilot results from a feasibility study utilizing Kernel's Flow technology to assess neuro-effects of ketamine. Conducted over 11 days, the study confirmed changes in functional connectivity consistent with existing research. Results will be presented at the PSYCH Symposium in London on May 11, 2022. This study, which received FDA Investigational New Drug authorization, paves the way for advancements in psychedelic therapeutics, highlighting the potential of real-time brain activity measurement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.85%
Tags
none
-
Rhea-AI Summary

Cybin announced that its deuterated psilocybin analog, CYB003, will be presented at the 'From Research to Reality' Global Summit on Psychedelic-Assisted Therapies, scheduled for May 27-29, 2022, in Toronto. The abstract, titled Pharmacological and Pharmacokinetic Profile of CYB003, indicates that CYB003 may offer therapeutic benefits over traditional psilocybin, including improved dosing accuracy and tolerability. Cybin aims to advance treatment options for mental health disorders through its innovative drug development strategies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.11%
Tags
none
Rhea-AI Summary

Cybin, a biopharmaceutical company, will have CEO Doug Drysdale presenting at the KCSA Psychedelics Virtual Investor Conference on April 28, 2022, at 11:00 a.m. ET. This live online event allows investors to interact and ask questions directly. Cybin focuses on developing therapeutics using psychedelics to address mental health issues through innovative drug discovery platforms and treatment regimens. Investors can register for the event via the provided link and access the archived webcast later.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
conferences

FAQ

What is the current stock price of Cybin (CYBN)?

The current stock price of Cybin (CYBN) is $9.61 as of December 20, 2024.

What is the market cap of Cybin (CYBN)?

The market cap of Cybin (CYBN) is approximately 185.2M.

What is Cybin Inc.?

Cybin Inc. is a biopharmaceutical company focused on developing psychedelic-based therapies for treating mental health conditions.

What does Cybin Inc. specialize in?

Cybin specializes in creating safe and effective treatments using psychedelic compounds to address psychiatric and neurological conditions.

What are the core areas of Cybin's research?

Cybin's research focuses on advancing psychedelic-based therapies, developing novel compounds, and improving drug delivery mechanisms.

What recent achievements has Cybin Inc. made?

Cybin has made significant progress in drug delivery technologies and the development of new chemical entities for mental health treatment.

Can you name some of Cybin's product candidates?

Cybin's pipeline includes CYB001 for major depressive disorder and CYB003 for anxiety disorders, among other candidates.

How does Cybin contribute to mental health treatment?

Cybin contributes by developing innovative psychedelic-based therapies aimed at providing effective treatments for various mental health conditions.

Has Cybin formed any strategic partnerships?

Yes, Cybin has established strategic partnerships and collaborations to support its research and clinical trials.

What is the significance of Cybin's drug delivery technologies?

Cybin's drug delivery technologies enhance the administration and therapeutic efficacy of psychedelic compounds.

What conditions are Cybin's therapies aimed at treating?

Cybin's therapies target psychiatric and neurological conditions such as depression, anxiety, and PTSD.

Where can I find the latest news about Cybin Inc.?

The latest news and updates about Cybin Inc. can be found on their official website and financial news platforms like StockTitan.

Cybin Inc.

NYSE:CYBN

CYBN Rankings

CYBN Stock Data

185.23M
18.64M
6.35%
36.61%
3.05%
Biotechnology
Healthcare
Link
United States of America
Toronto